Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacterales in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020

Aztreonam-avibactam is a drug combination pending phase 3 clinical trials and is suggested for treatment of severe infections caused by metallo-beta-lactamase (MBL)-producing by combining ceftazidime-avibactam and aztreonam. Beginning in 2019, four Antibiotic Resistance Laboratory Network regional l...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Antimicrobial agents and chemotherapy 2021-07, Vol.65 (8), p.e0048621-e0048621
Hauptverfasser:	Bhatnagar, Amelia, Boyd, Sandra, Sabour, Sarah, Bodnar, Janine, Nazarian, Elizabeth, Peinovich, Nadine, Wagner, Christine, Craft, Bradley, Snippes Vagnone, Paula, Simpson, Justin, Stone, Victoria N, Therrien, Michelle, Bateman, Allen, Lower, Danielle, Huang, Jennifer Y, Gumbis, Stephanie, Lonsway, David, Lutgring, Joseph D, Karlsson, Maria, Brown, Allison C
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Azabicyclo Compounds - pharmacology Aztreonam - pharmacology beta-Lactamases - genetics Ceftazidime Drug Combinations Drug Resistance, Microbial Humans Laboratories Microbial Sensitivity Tests Susceptibility
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!